Olanzapine in Chinese patients with schizophrenia or bipolar disorder: a systematic literature review
Hai Bo Haber Xue,1 Li Liu,1 Hena Zhang,2 William Montgomery,3 Tamás Treuer41Lilly Suzhou Pharmaceutical Co, Ltd, Shanghai Branch, Shanghai, 2China Pharmaceutical University, Nanjing, People’s Republic of China; 3Eli Lilly Australia Pty Ltd, West Ryde, Australia; 4Eli Lilly &...
Main Authors: | Xue HBH, Liu L, Zhang H, Montgomery W, Treuer T |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2014-05-01
|
Series: | Neuropsychiatric Disease and Treatment |
Online Access: | http://www.dovepress.com/olanzapine-in-chinese-patients-with-schizophrenia-or-bipolar-disorder--a16865 |
Similar Items
-
Comparison of clinical outcomes with orodispersible versus standard oral olanzapine tablets in nonadherent patients with schizophrenia or bipolar disorder
by: Novick D, et al.
Published: (2017-06-01) -
Clinical utility of orally disintegrating olanzapine in Chinese patients with schizophrenia: a review of effectiveness, patient preference, adherence, and other properties
by: Zhao J, et al.
Published: (2014-02-01) -
Does participation in a weight control program also improve clinical and functional outcomes for Chinese patients with schizophrenia treated with olanzapine?
by: Montgomery W, et al.
Published: (2014-07-01) -
Factors associated with early response to olanzapine and clinical and functional outcomes of early responders treated for schizophrenia in the People’s Republic of China
by: Ye W, et al.
Published: (2014-05-01) -
Correlation between changes in quality of life and symptomatic improvement in Chinese patients switched from typical antipsychotics to olanzapine
by: Montgomery W, et al.
Published: (2015-01-01)